ARZERRA (Novartis Pharmaceuticals Corporation)
Welcome to the PulseAid listing for the ARZERRA drug offered from Novartis Pharmaceuticals Corporation. This CD20-directed Cytolytic Antibody [EPC],CD20-directed Antibody Interactions [MoA] pharmaceutical is classified as a HUMAN PRESCRIPTION DRUG. Below, you can view details for this drug, such as its dosage form, route of delivery, start market/end market dates, and more. We have also randomly listed additional pharmaceuticals used in the same HUMAN PRESCRIPTION DRUG drug type category.
| LABELER NAME / MANUFACTURER: | Novartis Pharmaceuticals Corporation |
| NON-PROPRIETARY NAME: | ofatumumab |
| SUBSTANCE NAME: | OFATUMUMAB |
| TYPE: | HUMAN PRESCRIPTION DRUG |
| PHARMA CLASS: | CD20-directed Cytolytic Antibody [EPC],CD20-directed Antibody Interactions [MoA] |
| ROUTE: | INTRAVENOUS |
| DOSAGE FORM: | INJECTION, SOLUTION |
| MARKETING CATEGORY NAME: | BLA |
| START MARKETING DATE: | 2016-02-01 |
| END MARKETING DATE: | 0000-00-00 |
ARZERRA HUMAN PRESCRIPTION DRUG Details:
| Item Description | ARZERRA from Novartis Pharmaceuticals Corporation |
| LABELER NAME: | Novartis Pharmaceuticals Corporation |
| DEA SCHEDULE: |
|
| ACTIVE STRENGTH: | 20(mg/mL) |
| START MARKETING DATE: | 2016-02-01 |
| END MARKETING DATE: | 0000-00-00 |
| PRODUCT ID: | 0078-0669_330de426-198d-4db0-adee-073923a9f072 |
| PRODUCT NDC: | 0078-0669 |
| APPLICATION NUMBER: | BLA125326 |
Other OFATUMUMAB Pharmaceutical Manufacturers / Labelers:
